CAN04 development

A dual effect on cancer

Cantargia's CAN04 antibody treatment fights cancer by activating the immune system's killer cells and by blocking signals that lead to tumour growth. The target molecule, IL1RAP, is expressed in most common types of cancer, indicating a great potential of CAN04.

Preclinical development

Preclinical data has shown that IL1RAP is overexpressed by tumour cells from several different types of cancer. Furthermore, preclinical results show that a large number of cancer forms may be sensitive to CAN04 treatment. Additional studies are conducted to further document CAN04 during the clinical development. CAN04 works both by decreasing the tumour inflammation and by stimulating the immune system’s killer cells to eradicate the tumour cells. Effects of CAN04 on tumour development and on the immune system are studied in different cancer models. These studies include combination therapies. 

CAN04 has also been documented from a safety perspective. Treatment with repeat doses of up to 100 mg/kg has been proven safe in a concluding GLP (Good Laboratory Practice) toxicity study.

Clinical development

Clinical development is initially focusing on non-small cell lung cancer (NSCLC) and pancreatic cancer. During the first part of the phase I/IIa study CANFOUR safety and tolerability of CAN04 at escalating dose levels are being evaluated, while the second part is designed to obtain an initial indication of anti-tumour activity in the chosen types of cancer. CAN04 therapy is investigated both as monotherapy as well as in combination therapy. One further study is also planned to be conducted, which will look into mechanism of action and biomarkers during treatment of acute myeloid leukaemia (AML).


CAN04 is manufactured in a biological production system. A specific cell-line licensed from BioWa Inc. enables us to produce antibodies with a more potent ADCC (Antibody-dependent Cellular Cytotoxicity) activity. More information about this technology can be found at . The industrial manufacturing process has been developed by Glycotope Biotechnology GmbH (recently acquired by Celonic AG, who manufactures the product for use in pre-clinical and clinical trials. 

CAN04 is produced in cells cultivated in up to a 1000 litre scale and then purified in several steps to obtain a final product with high purity. 



If you have any questions or concerns please do not hesitate to contact us.

Contact us